Heart failure with preserved ejection fraction (HFpEF) is a growing public health problem that accounts for approximately half of all prevalent heart failure (HF). 1, 2 Once believed to carry a favorable prognosis compared with HF and reduced ejection fraction (HFrEF), contemporary data suggest that both groups face similar outcomes in the community setting. 1, 3 Although survival rates for patients with chronic HFrEF have improved in the last 2 decades with advances in drug and device-based therapies, there has been no such parallel progress in HFpEF management, 4 and treatment remains largely limited to the active recognition and treatment of comorbidities and the use of diuretics. The prevalence of HFpEF relative to HFrEF continues to rise at% 1% per year, projecting it to be the more common form of

HF over the next decade. 5, 6 HFpEF is particularly common in the elderly and is associated with a significant risk of death, hospitalization and suboptimal quality of life. Thus, there remains an enormous unmet need for effective therapy for this group of patients. 7, 8